Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Knee Arthroplasty
CompletedPhase 4NCT06470100
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Effect of perineurial dexamethasone and dexmedetomidine on erector spinal plane block duration for knee arthroplasty
Study details
- Official title
- Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Total Knee Arthroplasty
- Conditions
- Interventions
- Drug: 0.9% Sodium Chloride Injection
- Drug: Dexamethasone
- Drug: Dexmedetomidine
- Sponsor
- Poznan University of Medical Sciences
- Start date
- 2024-08-13
- Primary completion
- 2026-03-03
- Sex
- All
- Age range
- from 18 Years to 100 Years
- Results posted
- No results posted in this snapshot
- Countries
- Poland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * patients undergoing primary hip arthroplasty * aged \>18 years and \<100 years * ASA physical status 1, 2 or 3. Exclusion Criteria: * if they refused to participate, * had a history of opioid abuse, * had an infection of the site of needle puncture, * were less than 18 years of age, * were postponed as having ASA 4 or 5, * had an allergy to any of the drugs used in the study, * renal failure (estimated glomerular filtration rate \<15ml/min/1.73m2), * liver failure, * known or suspected coagulopathy, * pre-existing anatomical or neurological disorders in the lower extremities, * intellectual disability with problems in pain evaluation, * severe psychiatric illness.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06470100